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Abstract
Background: Early diagnosis of sepsis in pediatric patients is vital but remains a major challenge. Previous studies
showed that presepsin is potentially a reliable diagnostic biomarker for sepsis in adult and neonates. However,
there is no pooled analysis of its efficacy as a diagnostic biomarker for sepsis in children. The aims of the present
meta-analysis were to assess the overall diagnostic accuracy of presepsin in pediatric sepsis and compare it to
those for C-reactive protein (CRP) and procalcitonin (PCT).
Methods: A systematic literature search was performed in Medline/Pubmed, Embase, the Cochrane Library, and ISI
Web of Science to identify relevant studies reporting the diagnostic accuracy of presepsin in patients with pediatric
sepsis. Sensitivities and specificities were pooled by bivariate meta-analysis. Heterogeneity was evaluated by χ2 test.
Results: We identified 129 studies in total. Most were disqualified on the basis of their titles/abstracts and
duplication. Four studies were included in the final analysis. They comprised 308 patients aged between 1 mo and
18 y. The pooled diagnostic sensitivity and specificity of presepsin were 0.94 (95% confidence interval [CI]: 0.74–0.99)
and 0.71 (95% CI: 0.35–0.92), respectively. The pooled diagnostic odds ratio, positive likelihood ratio (LR), and negative
LR of presepsin were 32.87 (95% CI: 2.12–510.09), 3.24 (95% CI, 1.14–12.38), and 0.08 (95% CI, 0.01–0.74), respectively.
Heterogeneity was found in both sensitivity (χ2 = 11.17; P = 0.011) and specificity (χ2 = 65.78; P < 0.001). No threshold
effect was identified among the studies (r = − 0.938). The pooled sensitivity of presepsin (0.94) was higher than that of
CRP (0.51) and PCT (0.76), whereas the overall specificity of presepsin (0.71) was lower than that of CRP (0.81) and PCT
(0.76). The AUC of presepsin (0.925) was higher than that of CRP (0.715) and PCT (0.820).
Conclusion: Currently available evidence indicates that presepsin has higher sensitivity and diagnostic accuracy, but
lower specificity, than PCT or CRP in detecting sepsis in children. However, these results must be carefully interpreted
as the number of studies included was small and the studies were statistically heterogeneous.
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Background
Sepsis is a life-threatening condition. It is the leading cause
of death or morbidity in the pediatric population [1, 2]. The
epidemiology of pediatric sepsis varies [3], but an estimated
1.2 million children worldwide are stricken with it each year
[4]. Recent U.S. studies indicated that > 70,000 children
were hospitalized for sepsis at a cost of ~$5.0 billion and a
mortality rate of ≤20% [1, 5].
However, there has been limited research on pediatric
sepsis. Management of this condition has often been
adapted from guidelines for adult sepsis [6]. It is difficult
to define sepsis in the pediatric patient because of age-
dependent vital signs. Moreover, the seriousness of their
condition is often unclear [7]. Sepsis in children is usually
diagnosed on the basis of systemic inflammatory response
syndrome (SIRS) and a suspected or proven infection [7].
Infection is confirmed when the blood culture/stain/PCR
results are positive for a specific pathogen. Sepsis is sus-
pected on the basis of clinical, radiological, or laboratory
findings [7–9]. More recently, sepsis was defined as a life-
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threatening organ dysfunction resulting from the deregu-
lation of the host response to infection [10]. Nevertheless,
this criterion was formulated for adult sepsis patients.
Thus, additional guidelines that reflect age-specific sepsis
and stratify its risks for children are necessary [10]. Blood
culture remains the gold standard for the confirmation of
sepsis [11, 12].
On the other hand, blood culture has considerable
limitations such as prolonged time-to-result and false
negativity [13]. Delays in administration of the appropri-
ate antibiotics are associated with significant increases in
mortality and morbidity [14]. Therefore, biomarkers may
play a vital role in the timely diagnosis and management
of sepsis [15]. The most widely investigated diagnostic
biomarkers for pediatric sepsis are C-reactive protein
(CRP) and procalcitonin (PCT) [16]. However, CRP
alone lacks the specificity to discriminate bacterial, viral
and noninfectious inflammatory conditions [17]. The
prediction of sepsis is also inaccurate as its sensitivity is
low [17, 18].
PCT is a promising diagnostic marker for sepsis
[11, 19–21] but is inadequate for pediatric sepsis predic-
tion because its sensitivity and specificity are variable
[11, 22]. The large discrepancies between studies in terms
of their reported cutoff values limit the utility of these bio-
markers in clinical practice [20]. After the onset of infec-
tion or inflammation, CRP increases within 4–6 h and
peaks at 36–72 h [17, 23], while PCT rises within 2–4 h
and reaches its maximum at 24–36 h [24–27]. Thus, extra
care is necessary when using CRP and PCT as very early
biomarkers for sepsis.
CD (cluster of differentiation) 14 is a cell-surface
glycoprotein expressed in macrophages, monocytes, den-
dritic cells, and neutrophils [28]. CD14 is a lipopolysac-
charide (LPS) receptor. It transfer the LPS signal from
bacteria via Toll-like receptor-4 [29], triggers the release
of proinflammatory cytokines, and activates a systematic
inflammatory response [30]. Presepsin consists of the N-
terminal 13 kDa fragment of the CD14 protein [31]. Sev-
eral recent studies presented presepsin as a promising
diagnostic biomarker for adult sepsis [32–35]. A current
systematic review reported that presepsin had high sen-
sitivity and specificity in predicting neonatal sepsis [36].
Presepsin levels increase within 2 h and peak at 3 h after
the onset of infection [24]. Serum presepsin can be mea-
sured easily and rapidly [37]. Therefore, presepsin could
be a useful biomarker for the early diagnosis of sepsis.
Several clinical studies [38–41] proposed the diagnostic
value of presepsin in pediatric sepsis. However, there is
no published meta-analysis of its diagnostic efficacy in
pediatric sepsis patients.
Therefore, we conducted a systematic review and meta-
analysis to assess the diagnostic value of presepsin in
pediatric sepsis and compare it with other biomarkers.
Methods
This meta-analysis was conducted and reported in compli-
ance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Statement (PRISMA) [42].
Search strategy
Medline/Pubmed, Embase, the Cochrane Library, and
ISI Web of Science were searched for studies reporting
the performance of presepsin in the diagnosis of
pediatric sepsis. The search algorithms used for each
database are shown in Additional file 1. The search was
executed on February 13, 2019. Reference lists were also
screened for pertinent articles and all languages were in-
cluded in the search.
Study selection
Two reviewers (SHY) and (JGY) independently evaluated
the eligibility of the studies. In cases of disagreement, a
third reviewer (HYK) was also consulted. No date restric-
tions were applied to the study search. Studies included
were those reporting on the efficacy of serum presepsin in
the diagnosis of pediatric sepsis. The pediatric age range
was defined as > 4 wks weeks and < 18 y. All article titles
and abstracts were screened for relevance and eligibility.
Studies evaluating the accuracy of presepsin in the diag-
nosis of pediatric sepsis and those providing sufficient data
to extract a 2 × 2 contingency table were included. The
presence of infection was defined as microbiologically
confirmed (smear microscopy, culture method, or PCR)
or suspected as probable according to a clinical record re-
view [11]. Studies addressing catheter-related bloodstream
infections (CRBSI) were eligible as CRSBI is a bacteremia
originating from an intravascular device [43, 44]. Full texts
were retrieved for all articles meeting the aforementioned
criteria.
Articles were excluded if they did not address sepsis or
assess presepsin. Studies that did not separately consider
pediatric patients were also omitted. Reviews, letters, ed-
itorials, expert opinions, and animal experiments were
also ruled out. Finally, reports with overlapping data or
with insufficient data to calculate presepsin sensitivity or
specificity were eliminated.
Data extraction
The following variables were independently extracted by
two authors (SHY and JGA): first author, publication
year, country, type of study, clinical setting, age range at
diagnosis, sample size, number of patients and controls,
sample type, cutoff value, inclusion and exclusion cri-
teria, diagnostic references, and presepsin assay methods.
Authors were contacted by e-mail and additional data
were requested in the event of information gaps. For
studies consisting of multiple groups and/or different
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backgrounds, the analysis of each group was treated as a
single study.
Quality assessment
The methodological quality of each study was tested
with the Quality Assessment Tool for Diagnostic Accur-
acy Studies (QUADAS-2 score) [45]. This evaluation in-
cludes the following bias risk assessment domains:
patient selection, index test, reference standard, flow and
timing, sources of variation (applicability), and reporting
quality.
Statistical analysis
Accuracy data (true positive, false positive, false negative,
and true negative) were extracted for each study. A 2 × 2
contingency table was constructed to calculate sensitiv-
ity, specificity, positive and negative likelihood ratios
(LR), and diagnostic odds ratio (DOR) with their corre-
sponding 95% confidence intervals (95% CI). A value of
0.5 was added to all cells for studies with zero values to
correct for continuity. Results were evaluated by forest
plots. Heterogeneity of sensitivity and specificity was
evaluated by a χ2 test. P < 0.10 indicated significant het-
erogeneity. In this case, a bivariate random effects model
was adopted [46, 47].
The threshold effect is a major source of heterogeneity
in meta-analyses of diagnostic tests [48]. The studies in-
cluded used different cutoff values for presepsin in sepsis
diagnosis. Therefore, a threshold effect is anticipated.
Therefore, Spearman’s correlation coefficient (r) was cal-
culated. R ≥ 0.6 indicated a threshold effect [49].
Summary sensitivity and specificity were calculated
with a bivariate model and a hierarchical summary re-
ceiver operating characteristic (HSROC) model [48].
R v. 3.5.2 (http://www.R-project.org) was used for the
statistical and meta-analyses. Publication bias was mea-
sured with funnel plots. Egger’s test evaluated funnel
plot asymmetry [50]. The trim-and-fill method corrected
for any funnel plot asymmetry resulting from publication
bias [51].
Results
One hundred and twenty-nine published studies were
gleaned from our electronic database search. Of these,
113 were excluded after title and abstract screening and
the remaining 15 were subjected to full text reviews
(Fig. 1). Of these, seven had insufficient data to con-
struct a 2 × 2 contingency table and five did not include
children or adolescents.
Three studies met our criteria. Of these, one presented
two sets of results from different patients/controls. Thus,
it was included as a separate study. Thus, four studies
were included in our qualitative assessment and meta-
analysis [38–40] (Fig. 1). The characteristics of these
studies are listed in Table 1.
All eligible studies were published between 2016 and
2018. One was conducted in Turkey [38], one in Egypt
[39], and two in Slovakia [40]. Three of them were pro-
spective studies and one was retrospective. Three hun-
dred and eight patients were included in the four
studies. Of the 207 (67.2%) patients in the control group,
127 (61.4%) were categorized as non-sepsis patients and
80 (38.6%) as healthy volunteers. There were 101 pa-
tients with sepsis (32.8%).
Patient populations were heterogeneous (Table 1).
Three studies included patients with hematological malig-
nancy (HM), and one included patients with CRBSI. Of
the three studies with HM patients, one included those on
chemotherapy with febrile neutropenia [39] and the other
two included those presenting with fever, hypothermia,
chills, or other putative signs of sepsis [40].
Two studies identified sepsis patients by positive bac-
terial cultures [39, 40]. One study [38] defined sepsis pa-
tients according to the criteria of the Infectious Diseases
Society of America (IDSA) consensus conference (2009)
[44]. Another study [40] designated sepsis patients based
on the modified International Pediatric Sepsis Consensus
Conference definition (IPSCC) (2005) [7].
One study used serum [38], one used plasma [39], and the
other used unspecified blood samples [40] to test for sepsis.
Three studies used PATHFAST [39, 40], and another used
ELISA [38] to assay for presepsin. The presepsin cutoff
values for sepsis detection ranged from 240 to 1014 pgmL-l.
Quality assessment
The output of the QUADAS-2 tool is summarized in
Fig. 2. Two studies evaluated the optimal cutoff value to
calculate sensitivity and specificity instead of using the
predefined value scored ‘high risk’ in the index test do-
main. In terms of the patient selection domain, the risk
of bias was low in most studies as they clearly defined
their exclusion criteria. Two studies did not include all
patients in their analyses and were scored ‘unclear’ in
the patient flow and timing domains. All studies had low
risk in the reference standard domain as they used posi-
tive blood culture, the guidelines of the IDSA consensus
conference [44], and the IPSCC definition [7] to diag-
nose sepsis.
Most of the studies scored ‘unclear’ in terms of the pa-
tient selection domain as the majority of the enrolled
patients had HM. One study scored ‘unclear’ in the refer-
ence standard domain as it defined the disease condition
as CRBSI which limited its applicability.
Meta-analysis for diagnostic accuracy
Descriptive statistics of the diagnostic accuracy of pre-
sepsin are presented in the form of a forest plot in Fig. 3.
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Significant heterogeneity between studies was noted in
terms of sensitivity (χ2 = 11.17; P = 0.0108) and specificity
(χ2 = 65.78; P < 0.0001). Spearman’s correlation coeffi-
cient (r) was − 0.938 (95% CI; − 0.999 to 0.234). Thus,
there was no threshold effect (Additional file 2).
Summary estimates of sensitivity, specificity, positive
LR, negative LR, and DOR were calculated with a bivari-
ate random effects model (Table 2). The overall sensitiv-
ity was 0.94 (95% CI; 0.74–0.99) and the specificity was
0.71 (95% CI; 0.35–0.92). The area under the [HSROC]
curve (AUC) was 0.925 (Fig. 4). Therefore, presepsin had
a high diagnostic accuracy for pediatric sepsis.
An asymmetric funnel plot and Egger’s test (P =
0.0001) revealed publication bias among the studies
(Additional file 3). The trim-and-fill method was applied
for bias correction and showed log DOR = 2.39 for pre-
sepsin corresponding to a pooled DOR = 10.91 (Fig. 5).
The presepsin cutoff value for detecting pediatric sep-
sis varies, ranging from 240 to 1014 pg/ml. Mean cutoff
value was 635.8 pg/ml. Due to the varied cutoff values
between studies, we conducted subgroup analysis using
a cutoff value of 650 pg/ml. Two studies [38, 39] fea-
tured cutoff values higher than 650 pg/ml and the other
two studies [40] had cutoff values lower than 650 pg/ml.
We found higher pooled sensitivity (0.84 vs. 0.99) and
specificity (0.42 vs. 0.90) in the studies where cutoff
value was greater than 650 pg/ml. This cutoff value fea-
tured higher diagnostic accuracy as well (AUC 0.827 vs.
0.983) (Table 3, Additional file 4).
Comparison of the performances of presepsin, CRP, and
PCT
Three studies compared presepsin with CRP and PCT.
Two of these defined the patient by positive blood
Fig. 1 Flow diagram of the study selection process
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Fig. 2 Quality Assessment of the Diagnostic Accuracy Studies-2 (QUADAS-2) criteria for the included studies
Table 1 Summary of the included studies
No Author
(Year)
Country Type of
study
Age
(range)
Sample
Size (all)
Patients/
control
(n)
Cutoff
(ng
mL-l)
Sample Inclusion
criteria
Exclusion References Assay
1 Tanır
Basaranoglu
2018
Turkey Prospective 1mo–
18 y
138 58
sepsis/
80
(healthy
controls)
990 serum 1 mo–18 y,
clinical signs
of CRBSI
received
antibiotics
within the 24 h
of presentation
with fever
2009 IDSA
guideline
ELISA
2 Baraka
2018
Egypt Case-
control
2–15 y 60 18
sepsis/
42 (non-
sepsis
patients)
1014 plasma < 16 y,
pediatric
patients with
HM, during
episodes of
fever and
neutropenia
after
receiving CTx
age > 16 y, non-
HM pediatric
patients, not on
chemotherapy
blood
culture
PATHFAST
3 Plesko
2016–1
Slovakia Prospective 1.5–
18.9 y
55 12
sepsis/
43 (non-
sepsis
patients)
240 unspecified < 18.9 y,
pediatric
patients with
HM, the
presence of
fever,
hypothermia,
chills, or
another sign
of possible
sepsis
Febrile episodes
thought to be
an adverse
effect of CTx,
not having
blood culture
drawn, patients
with proven
non-bacterial
infection
blood
culture
PATHFAST
3 Plesko
2016–2
Slovakia Prospective 1.5–
18.9 y
55 13
sepsis/
42 (non-
sepsis
patients)
299 unspecified < 18.9 y,
pediatric
patients with
HM, the
presence of
fever,
hypothermia,
chills, or
another sign
of possible
sepsis
Febrile episodes
thought to be
an adverse
effect of CTx,
not having
blood culture
drawn, patients
with proven
non-bacterial
infection
modified
IPSCC
definition
(2005)
PATHFAST
CRBSI catheter-related blood stream infection, CTx chemotherapy, HM hematologic malignancy, IDSA Infectious Diseases Society of America, IPSCC International
Pediatric Sepsis Consensus Conference
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culture [38, 40] and one used the modified IPSCC defin-
ition [40]. Descriptive statistics of the diagnostic accur-
acy of CRP and PCT for sepsis detection are presented
in a forest plot (Fig. 3) and summarized in Table 2.
The pooled sensitivity of presepsin was higher than
those of CRP and PCT [presepsin: 0.94 (95% CI: 0.74–
0.99); CRP: 0.51 (95% CI: 0.24–0.78); PCT: 0.76 (95% CI:
0.59–0.88)]. In contrast, the pooled specificity of presep-
sin was lower than that of CRP and PCT [presepsin: 0.71
(95% CI: 0.35–0.92); CRP: 0.81 (95% CI: 0.53–0.94);
PCT: 0.76 (95% CI: 0.67–0.83)]. The AUC of presepsin
(0.925) was higher than that of CRP (0.715) and PCT
(0.830) (Fig. 4) Thus, presepsin had a higher diagnostic
performance than CRP or PCT. Threshold effects could
not be calculated for CRT and PCT as there were too
few studies involving them. Funnel plots of the studies
including CRP and PCT indicated no publication bias
(Additional file 3).
Fig. 3 Forest plots of the sensitivity and specificity of presepsin, C-reactive protein (CRP), and procacitonin (PCT) for the diagnosis of pediatric sepsis
Table 2 Summary estimates of the diagnostic accuracy of presepsin, C-reactive protein, procalcitonin to diagnose pediatric sepsis
Author(s) and year Sensitivity
(95% CI)
Specificity
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI)
DOR
(95% CI)
Presepsin
Plesko 2016–1 0.81 [0.54, 0.94] 0.28 [0.17, 0.43] 1.13 [0.82, 1.56] 0.68 [0.20, 2.27] 1.67 [0.36, 7.67]
Plesko 2016–2 0.82 [0.56, 0.94] 0.57 [0.42, 0.71] 1.91 [1.25, 2.91] 0.31 [0.10, 0.99] 6.09 [1.37, 27.17]
Tanir Basaranoglu 2017 0.99 [0.92, 1.00] 0.93 [0.86, 0.97] 14.60 [6.51, 32.73] 0.01 [0.001, 0.14] 1606.09 [87.05, 29,633.96]
Baraka 2018 0.97 [0.79, 1.00] 0.85 [0.71, 0.93] 6.44 [3.16, 13.13] 0.03 [0.002, 0.48] 207.77 [11.09, 3892.29]
Bivariate summary estimates (95% CI) 0.94 [0.74, 0.99] 0.71 [0.35, 0.92] 3.24 [1.14, 12.38] 0.08 [0.01, 0.74] 32.87 [2.12, 510.09]
CRP
Plesko 2016–1 0.28 [0.14, 0.49] 0.95 [0.85, 0.98] 5.43 [1.38, 21.38] 0.76 [0.58, 0.99] 7.17 [1.50, 34.24]
Plesko 2016–2 0.50 [0.29, 0.72] 0.71 [0.58, 0.82] 1.74 [0.92, 3.29] 0.70 [0.42, 1.16] 2.48 [0.81, 7.60]
Baraka 2018 0.76 [0.54, 0.90] 0.66 [0.51, 0.79] 2.26 [1.39, 3.69] 0.36 [0.16, 0.82] 6.33 [1.85, 21.72]
Bivariate summary estimates (95% CI) 0.51 [0.24, 0.78] 0.81 [0.53, 0.94] 2.68 [0.51, 13.00] 0.60 [0.23, 1.43] 4.63 [2.16, 9.95]
PCT
Plesko 2016–1 0.80 [0.59, 0.91] 0.68 [0.53, 0.80] 2.47 [1.54, 3.97] 0.30 [0.13, 0.71] 8.18 [2.44, 27.43]
Plesko 2016–2 0.66 [0.42, 0.84] 0.79 [0.67, 0.88] 3.19 [1.67, 6.08] 0.43 [0.22, 0.86] 7.36 [2.14, 25.32]
Baraka 2018 0.97 [0.79, 1.00] 0.80 [0.66, 0.89] 4.93 [2.69, 9.04] 0.03 [0.002, 0.51] 150.18 [8.20, 2750.01]
Bivariate summary estimates (95% CI) 0.76 [0.59, 0.88] 0.76 [0.67, 0.83] 3.17 [1.79, 5.18] 0.32 [0.61, 0.14] 11.88 [3.49, 40.47]
Bivariate summary estimates (95% CI) (Total) 0.79 [0.60, 0.90] 0.75 [0.61, 0.86] 3.16 [1.54, 6.43] 0.28 [0.66, 0.12] 10.76 [4.31, 26.83]
CRP C-reactive protein, PCT procalcitonin, CI confidence interval, LR likelihood ratio, DOR diagnostic odds ratio
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Discussion
The present study summarizes the overall perform-
ance of presepsin in the diagnosis of pediatric sepsis
and is based on currently available literature. To the
best of our knowledge, this is the first systematic re-
view and meta-analysis to evaluate the diagnostic
value of presepsin for pediatric sepsis (not including
neonates). Presepsin had high sensitivity and moder-
ate specificity. Presepsin also displayed high diagnostic
performance in predicting pediatric sepsis. Thus,
presepsin may be a useful diagnostic biomarker for
pediatric sepsis.
To date, several meta-analyses of the diagnostic ac-
curacy of presepsin in adult sepsis have been published.
They reported pooled sensitivities ranging from 0.78–
0.86, pooled specificities ranging from 0.73–0.83, posi-
tive likelihood ratios ranging from 3.40–4.63, negative
likelihood ratios ranging from 0.18–0.22, DOR ranging
from 14.25–22.0, and AUC ranging from 0.86–0.89
[32–35, 52, 53]. Two recent meta-analyses indicated
pooled presepsin sensitivities and specificities each in
the range 0.9–0.91 for the diagnosis of neonatal sepsis
[36, 54]. The DOR was in the range 120.94–170.28 and
the AUC was in the range 0.968–0.975 [36, 54]. The
present study showed higher sensitivity and similar spe-
cificity of presepsin for the diagnosis of pediatric sepsis
relative to those for adult sepsis. For the diagnosis of
pediatric sepsis, however, presepsin had similar sensi-
tivity and lower specificity compared to neonatal sepsis
analysis. As it has high sensitivity, presepsin may be
very useful for the exclusion of sepsis in pediatric pa-
tients when the level of this biomarker is normal or
lower than the cutoff value. Nevertheless, the specificity
of presepsin is only moderate. Consequently, it may be
necessary to diagnose sepsis by correlating it with clin-
ical symptoms as false positives could occur.
Presepsin level according to the etiologies of sepsis
Acute-phase reactants, such as CRP, PCT, and presepsin
are a class of serum proteins that change in response to
Fig. 4 Hierarchical summary receiver operating characteristic (HSROC) curve of the diagnostic accuracy of presepsin, C-reactive protein (CRP), and
procalcitonin (PCT) for pediatric sepsis. Summary points of the sensitivity and specificity, HSROC curve, 95% confidence region, and 95%
prediction region are provided. The area under the curve of the HSROC for presepsin, CRP, and PCT were 0.925, 0.715, and 0.820, respectively
Fig. 5 Trim-and-fill funnel plot of the log of diagnostic odds ratio
(DOR) of presepsin to diagnose pediatric sepsis. The x-axis represents
the study result [log (DOR)]. The y-axis represents the study precision
[the standard error of log (DOR)]. Each filled dot represents one study
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inflammation from infections, surgery, trauma, auto-
immune disorders, and malignancy [15, 55, 56]. The
level of acute phase reactants usually reflects the pres-
ence and degree of an inflammatory process so they are
thought to have the potential capacities in early diagno-
sis by differentiating sepsis from non-infectious systemic
inflammation, as prognostic implications, and in anti-
biotic guidance strategies [15, 57–59]. However, it is
believed that the level of acute phase reactant is not spe-
cific to any particular disease, nor can they precisely
distinguish infection from other etiologies of acute and
chronic inflammation [56, 60, 61]. Furthermore, there
are still not enough studies to show whether the level of
acute phase reactants would change according to the
specific microorganism [15, 61, 62].
In our review, two studies reported the level of prese-
pin according to the causing organisms. One study [38]
showed that median presepsin values were similar within
the groups of microorganisms; the median presepsin
value was 1668 pg/ml (range: 1048–2935) for gram-posi-
tive bacteremia patients, 1756 pg/ml (range: 1103–2033)
for gram-negative bacteremia patients, and 1406 pg/ml
(range: 1348–1566) for candidemia patients.
The other study [40] reported that the mean log value
of presepsin was 2.47 (SD 0.13) (pg/ml) for gram positive
bacteremia patients and 2.64 (SD 0.29) (pg/ml) for gram
negative bacteremia patients with no statistical differ-
ence (P = 0.237). However, we could not conduct sub-
group analysis due to insufficient data.
Cut off values of presepsin for diagnosing sepsis
Cutoff value of presepsin for diagnosing sepsis varies ac-
cording to the different reference tests, controls, and
clinical settings. In recent adult meta-analysis, cutoff
values ranged from 317 to 849 pg/ml and the optimal
cut off value was 600–650 pg/ml [35]. The authors found
similar sensitivity (0.85 vs. 0.84) but lower pooled speci-
ficity in the cutoff values greater than 700 pg/ml studies,
compared to values smaller than 700 pg/ml studies (0.59
vs. 0.80) [35]. In recent neonatal meta-analysis, presepsin
cutoff value ranged from 304.5 to 885.0 pg/ml and when
using a cutoff value < 600 ng/L, sensitivity was 0.93, with
a specificity of 0.81 and AUC 0.8195; using a cut-off
value of > 600 ng/L resulted in sensitivity of 0.87 and
specificity of 0.97, with higher diagnostic accuracy
(AUC 0.976) [54]. However, the other neonatal meta-
analysis reported that its diagnostic efficacy was maxi-
mized (sensitivity 0.91, specificity 0.97, AUC 0.99)
when using a presepsin cutoff value ranging from 650
to 850 pg/ml [36].
In our study, the presepsin cutoff value for detecting
pediatric sepsis varies, ranging from 240 to 1014 pg/ml.
We found higher pooled sensitivity, specificity and diag-
nostic accuracy in the cutoff value greater than 650 pg/
ml. However, a small sample size and heterogeneous
characteristics of included studies are limitations disal-
lowing the application of these results from clinical prac-
tice at this stage.
Comparison of CRP, and PCT as diagnostic biomarkers for
sepsis
CRP and PCT are the most commonly used diagnostic
biomarker for pediatric sepsis and their diagnostic ac-
curacies have been extensively studied [16, 25]. Several
clinical studies showed that PCT has higher diagnostic
accuracy than CRP in the differentiation of sepsis and
SIRS (PCT: AUC = 0.71–0.99; CRP: AUC = 0.54–0.65)
[63, 64]. A recent meta-analysis investigated the diagnos-
tic accuracy of PCT in the distinction of sepsis from
SIRS. PCT had good sensitivity (pooled, 0.78) and poor
specificity (pooled, 0.57) at a cutoff value of < 2.0 ng mL-l
in pediatric patients older than neonates [11].
Several head-to-head comparisons were made between
presepsin and PCT or CRP in adult patients. A recent
adult patient meta-analysis disclosed no statistically sig-
nificant difference in the diagnostic accuracy of sepsis
between presepsin and CRP (presepsin: AUC = 0.85;
CRP: AUC = 0.85) or between presepsin and PCT (pre-
sepsin: AUC = 0.87; PCT: AUC = 0.86) [35]. For studies
conducted on patients in intensive care units, the pooled
sensitivity of presepsin was higher than that of PCT
(0.88 vs. 0.75), but lower than that of PCT (0.58 vs. 0.75)
[35]. Another meta-analysis compared the diagnostic
value of PCT with that of presepsin for sepsis in critic-
ally ill adult patients. The pooled sensitivities (0.84 for
presepsin and 0.8 for PCT) and specificities (0.73 for
presepsin and 0.75 for PCT) did not significantly differ
between the two biomarkers [65].
Presepsin may be the most accurate biomarker of neo-
natal sepsis. One study showed that presepsin had higher
Table 3 Diagnostic accuracy of presepsin according to the cut off value
Number of
studies
Sensitivity (95%
CI)
Specificity (95%
CI)
Positive LR (95%
CI)
Negative LR (95%
CI)
DOR (95% CI) AUC
Cutoff ≤650 pg/
ml
2 0.84 [0.64, 0.94] 0.42 [0.18, 0.71] 1.45 [0.78, 3.24] 0.38 [0.08, 2.00] 3.81 [1.03, 14.04] 0.827
Cutoff > 650 pg/
ml
2 0.99 [0.88, 1.00] 0.90 [0.78, 0.96] 9.9 [4.00, 25.00] 0.01 [0.001, 0.15] 580.75 [73.53,
4586.94]
0.983
CI confidence interval, LR likelihood ratio, DOR diagnostic odds ratio, AUC area under the receiver operating characteristic curve
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AUC than CRP (0.975 vs. 0.858) and PCT (0.959 vs.
0.783) [36]. In the present study, the overall sensitivity of
presepsin was higher than that of CRP (0.94 vs. 0.51)
and PCT (0.94 vs. 0.76). However, the overall specificity
of presepsin was lower than that of CRP (0.71 vs. 0.81)
and PCT (0.71 vs. 0.76). Moreover, the AUC of presep-
sin was higher than that of CRP (0.925 vs. 0.715) and
PCT (0.925 vs. 0.830). These results suggest that the
overall diagnostic performance of presepsin is greater
than that of CRP and PCT. Furthermore, presepsin
levels increase earlier in response to sepsis than either
CRP or PCT [24]. Thus, presepsin may be promising as
a sensitive biomarker for the early diagnosis of sepsis in
pediatric patients.
To the best of our knowledge, this systematic review
and meta-analysis is the first to evaluate the perform-
ance of presepsin as a diagnostic biomarker of sepsis in
pediatric patients (excluding neonates) and to compare
it with PCT and CRP. Nevertheless, our study had sev-
eral limitations. First, only four publications were in-
cluded as there was relatively little currently available
data for pediatric sepsis patients. Second, differences in
the reference standards, control group definitions, and
specimen types in the included studies are possible
sources of heterogeneity. Moreover, we could not con-
duct a subgroup analysis as the number of included
studies was very small. Third, the included studies com-
prised mainly enrolled HM pediatric patients. Three of
four studies included in the meta-analysis were con-
ducted in pediatric patients with hematologic malignan-
cies. Thus, this is a major limitation of the study, and
the conclusions cannot be generalized for all pediatric
populations. Therefore, a more prospective clinical study
with a larger sample size is necessary to compensate for
the aforementioned deficiencies.
Conclusions
Presepsin showed higher sensitivity and accuracy but
relatively lower specificity for the diagnosis of pediatric
sepsis than either PCT or CRP.
Owing to the small number and heterogeneity of the
included studies, however, the foregoing results should
be carefully interpreted and applied. Future clinical trials
are required to validate and determine the optimal pre-
sepsin cutoff for the diagnosis of sepsis in children.
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